

Supplementary Table S2. Time-to-event analysis for overall survival and recurrence free survival

				Overall survival		Recurrence free survival	
				p-value	HR ^a (95% CI)	p-value	HR ^a (95% CI)
Primary CRC	PSMA	(concurrent metastasis) (n = 41)					
	PSMA high vs. low ^a			.088	2.154 (0.891–5.204)	.165	5.480 (0.496–60.520)
Hepatic metastasis	PSMA	(concurrent metastasis) (n = 41)					
	PSMA high vs. low ^a			.264	0.546 (0.189–1.578)	.334	0.348 (0.041–2.961)
Hepatic metastasis	PSMA	(concurrent metastasis and untreated) (n = 34)					
	PSMA high vs. low ^a			.188	0.441 (0.131–1.490)	.458	0.429 (0.046–4.003)

HR, hazard ratio; CI, confidence interval; PSMA, prostate-specific membrane antigen.

^aPSMA low (PSMA/CD34 ratio < 50%) group was used as a reference.